For research and educational purposes only. Not medical advice.
YK-11 Reference
Educational, not medical advice reference for YK-11: SARM, Recovery; regulatory status, evidence posture, source review, and schedule notes. Als…
Reference summary
Published work is preclinical, focused on myogenic-cell follistatin induction and muscle-protein synthesis in cell culture. No human trials.
Regulatory and posture
- Categories
- SARM, Recovery
- Aliases
- Steroidal SARM, Myostatin-inhibitor-class compound
- Evidence posture
- preclinical - FDA enforcement attention. Sold only as a research chemical, not for human consumption per legal seller terms. WADA-prohibited under category S1.2 at all times. Steroidal skeleton - closer to anabolic-androgen pharmacology than non-steroidal SARMs; hepatotoxicity and HPTA suppression are reported in user accounts. No FDA-approved drug label.
- Regulatory status
- No FDA-approved YK-11 drug label. WADA prohibits SARMs under category S1.2 at all times. FDA enforcement against SARMs sellers applies. YK-11 is a steroidal scaffold compound - pharmacologically closer to anabolic-androgen pharmacology than non-steroidal SARMs.
- Content review status
- research reference
Selected public sources
- FDA consumer update: SARMs are not FDA-approved and cannot be legally marketed as dietary supplements
- WADA prohibited list: SARMs are category S1.2 anabolic agents prohibited at all times
- PubMed search: YK-11 myostatin steroidal SARM literature
Related tools
- Protocol builder overview - Public overview of the Pro protocol builder.